| 000 | 01681 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250516114050.0 | ||
| 264 | 0 | _c20131126 | |
| 008 | 201311s 0 0 eng d | ||
| 022 | _a1442-200X | ||
| 024 | 7 |
_a10.1111/j.1442-200X.2012.03733.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFuke, Toshiya | |
| 245 | 0 | 0 |
_aMizoribine requires individual dosing due to variation of bioavailability. _h[electronic resource] |
| 260 |
_bPediatrics international : official journal of the Japan Pediatric Society _cDec 2012 |
||
| 300 |
_a885-91 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aBiological Availability |
| 650 | 0 | 4 | _aChild |
| 650 | 0 | 4 | _aChild, Preschool |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aLupus Nephritis _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibonucleosides _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aAbe, Yoshifusa | |
| 700 | 1 | _aHibino, Satoshi | |
| 700 | 1 | _aTakeshi, Mikawa | |
| 700 | 1 | _aSaito, Takako | |
| 700 | 1 | _aSakurai, Shunsuke | |
| 700 | 1 | _aWatanabe, Shuichiro | |
| 700 | 1 | _aMurayama, Jun-ichiro | |
| 700 | 1 | _aItabashi, Kazuo | |
| 700 | 1 | _aNakano, Yasuko | |
| 773 | 0 |
_tPediatrics international : official journal of the Japan Pediatric Society _gvol. 54 _gno. 6 _gp. 885-91 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1442-200X.2012.03733.x _zAvailable from publisher's website |
| 999 |
_c22161183 _d22161183 |
||